Prescribing Naloxone for Opioid Overdose Intervention

Abstract

To provide an update on prescription of naloxone as a harm-reduction strategy, PubMed was searched to identify publications relevant to naloxone prescribing for reversal of opioid overdose. Opportunities now exist to expand naloxone use, although evidence suggests these are often missed or underexploited. The US FDA has approved an intranasal naloxone spray and an autoinjector naloxone formulation for community use. Effective use of naloxone in community settings requires screening to identify patients at risk of opioid overdose, discussing naloxone use with patients and their relatives, and providing appropriate training. The tools exist to expand the use of naloxone more widely into the community, thereby creating an opportunity to reduce opioid overdose fatalities.

Keywords::

• drug overdose
• harm-reduction strategy
• intranasal drug administration
• naloxone
• opioid antagonists

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Background information and manuscript preparation support were provided, under the direction of RB Dunne, by Nancy Holland and Michael Shaw, Synchrony Medical Communications, LLC, PA, USA, and sponsored by Adapt Pharma, Inc., PA, USA.